Product Overview

Cilacar 5 mg (Cilnidipine) is a prescription antihypertensive medication manufactured by J. B. Chemicals and Pharmaceuticals Ltd. Each strip contains ten film‑coated tablets, each delivering a precise 5 mg dose of the calcium‑channel blocker cilnidipine. The product is formulated for the management of elevated blood pressure in adult patients and is offered in pack sizes of 30, 60, or 90 tablets to support chronic treatment regimens. Orders are typically processed within six to fifteen days, providing a reliable supply chain for patients who require consistent therapy. The tablets are packaged in a moisture‑resistant strip to maintain potency throughout the shelf life, which is clearly indicated on the label.

What is Cilacar 5 mg (Cilnidipine)

Cilacar belongs to the dihydropyridine subclass of calcium‑channel blockers. The active moiety, cilnidipine, selectively inhibits L‑type voltage‑gated calcium channels located on vascular smooth‑muscle cells, resulting in vasodilation and a reduction in peripheral vascular resistance. This pharmacologic action leads to a decrease in both systolic and diastolic arterial pressure without causing a substantial increase in heart rate, making it particularly suitable for patients with concomitant coronary artery disease. The 5 mg strength represents the standard therapeutic dose for most adults with primary hypertension who do not have significant renal impairment. The tablet’s film‑coated coating ensures uniform dissolution and protects the drug from gastric degradation, allowing for once‑daily administration at the same time each day.

Uses and Benefits

The primary therapeutic indication for Cilacar 5 mg is the treatment of high blood pressure, medically termed hypertension. Consistent use of the medication can attenuate the risk of serious cardiovascular events such as myocardial infarction, ischemic stroke, and progression of chronic kidney disease. Clinical studies have demonstrated that patients experience a measurable decline in ambulatory blood‑pressure readings within two to three weeks of regular dosing, with maximal efficacy often observed after four to six weeks of continuous therapy. In addition, Cilacar is frequently incorporated into combination regimens with other antihypertensive classes, such as angiotensin‑converting enzyme inhibitors or thiazide diuretics, to achieve target blood‑pressure control in individuals with more complex disease profiles.

How It Works

The antihypertensive effect of cilnidipine is mediated through its antagonism of L‑type calcium channels, which reduces calcium influx into vascular smooth‑muscle cells. This inhibition leads to relaxation of arterial walls, resulting in decreased systemic vascular resistance and lowered arterial pressure. Because the drug exhibits limited impact on cardiac contractility and heart rate, it is generally well tolerated in patients who require long‑term blood‑pressure management without the risk of reflex tachycardia. The pharmacokinetic profile of cilnidipine includes rapid absorption after oral administration, followed by hepatic metabolism via the CYP3A4 enzyme pathway, and subsequent renal excretion of metabolites. This metabolic route allows for predictable drug interactions that can be managed through dose adjustments when co‑administered with strong CYP3A4 inhibitors or inducers.

Dosage Guidelines

For most adult patients, the recommended initial dosage of Cilacar is one 5 mg tablet administered orally once daily, preferably at the same time each day to maintain steady plasma concentrations. The tablet should be swallowed whole with a full glass of water and may be taken with or without food, as its bioavailability is not significantly affected by meals. If blood‑pressure targets are not achieved after a four‑week trial, a healthcare provider may consider increasing the dose, adding another antihypertensive agent, or adjusting the dosing schedule. Patients with mild to moderate hepatic impairment are advised to start with a reduced dose, while the medication is contraindicated in individuals with severe renal insufficiency or a known hypersensitivity to cilnidipine. Proper storage at room temperature, away from moisture and direct sunlight, helps preserve tablet integrity throughout the treatment period.

Side Effects

Like all prescription medications, Cilacar may be associated with adverse effects, although most are mild and self‑limiting. The most frequently reported side effects include headache, facial flushing, peripheral edema, and dizziness, which typically resolve without medical intervention. Less common but clinically significant reactions can involve bradycardia, constipation, and transient elevations in hepatic enzymes, warranting periodic laboratory monitoring in high‑risk patients. Although rare, serious hypersensitivity reactions such as skin rash, itching, or swelling of the face and throat require immediate discontinuation of the drug and emergency medical care. Patients should be instructed to report any persistent chest pain, severe shortness of breath, or signs of electrolyte imbalance to their physician promptly.

Warnings and Precautions

Prior to initiating therapy with Cilacar 5 mg, a comprehensive medical assessment is essential. Individuals should disclose any history of heart failure, liver disease, electrolyte disturbances, or peripheral vascular conditions to their prescribing clinician. The medication is contraindicated during pregnancy and lactation unless the anticipated benefit justifies potential fetal or infant risk, and it should not be used in children unless specifically indicated. Concomitant administration of strong CYP3A4 inhibitors (such as ketoconazole or clarithromycin) may increase cilnidipine exposure, necessitating dose reduction, while strong inducers (such as rifampicin) may diminish efficacy. Alcohol consumption should be moderated, as it can potentiate the blood‑pressure‑lowering effect and increase the likelihood of dizziness. Patients are encouraged to maintain a healthy lifestyle, including a balanced diet and regular physical activity, to enhance overall cardiovascular risk reduction. For additional safety information, refer to the U.S. Food and Drug Administration and National Institutes of Health.

Frequently Asked Questions

1. Can Cilacar be taken with other blood‑pressure medications? Yes, it is commonly prescribed alongside angiotensin‑converting enzyme inhibitors, angiotensin receptor blockers, or thiazide diuretics. However, clinicians usually monitor blood pressure closely after any dose change to ensure that the combined effect does not lower pressure too far, and they may adjust doses as needed to achieve the desired therapeutic target safely.
2. How long does it take to notice a reduction in blood pressure? Most patients observe a modest but measurable decline in sitting and ambulatory blood‑pressure readings within one to two weeks of consistent daily use. Full therapeutic effect is often reached after four to six weeks, at which point the medication can help maintain blood pressure within the target range defined by the treating physician.
3. Is the medication suitable for elderly patients? Clinical experience supports the use of Cilacar in older adults, but clinicians typically start with the lowest effective dose and monitor renal function regularly. Dose adjustments may be necessary due to age‑related declines in kidney function, and close follow‑up helps ensure safety and efficacy in this population.
4. What should I do if I miss a dose? If a dose is missed, take it as soon as you remember unless it is almost time for the next scheduled dose; in that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed tablet, as this could increase the risk of side effects.
5. Where can I find more detailed prescribing information? The official product monograph, available on the manufacturer’s website, provides comprehensive dosing, contraindications, and safety data. Additional guidance can also be obtained from authoritative sources such as the U.S. Food and Drug Administration and MedlinePlus, which offer evidence‑based information on hypertension management.

Related Products

• Cilnidipine 5 mg (Generic)
• Nicardia XL 30 Mg (Nifedipine)
• Cilacar (Cilnidipine)
• Cilacar 10mg (Cilnidipine)
• Cilacar 20mg (Cilnidipine)
• Cilacar T (Cilnidipine/Telmisartan)
• Arkamin 100 (Clonidine)
• Abel 40 mg (Azilsartan Medoxomil)
• Metrogyl Gel (Metronidazole)
• Metrogyl Tablet (Metronidazole)
• Metrogyl 200mg (Metronidazole)
• Metrogyl 400mg (Metronidazole)